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Abstract
Background: Tomotherapy-based total body irradiation (TBI) is performed using the head-first position (HFP) and
feet-first position (FFP) due to treatment length exceeding the 135 cm limit. To reduce the dosimetric variation at
the match lines, we propose and verify a volumetric gradient matching technique (VGMT) by combining
TomoHelical (TH) and TomoDirect (TD) modes.
Methods: Two planning CT image sets were acquired with HFP and FFP using 15 × 55 × 18 cm3 of solid water
phantom. Planning target volume (PTV) was divided into upper, lower, and gradient volumes. The junction
comprised 2-cm thick five and seven gradient volumes (5-GVs and 7-GVs) to create a dose distribution with a
gentle slope. TH-IMRT and TD-IMRT plans were generated with 5-GVs and 7-GVs. The setup error in the calculated
dose was assessed by shifting dose distribution of the FFP plan by 5, 10, 15, and 20 mm in the longitudinal
direction and comparing it with the original. Doses for 95% (D95) and 5% of the PTV (D5) were calculated for all
simulated setup error plans. Absolute dose measurements were performed using an ionization chamber in the
junction.
Results: The TH&TD plan produced a linear gradient in junction volume, comparable to that of the TH&TH plan. D5
of the PTV was 110% of the prescribed dose when the FFP plan was shifted 0.7 cm and 1.2 cm in the superior
direction for 5-GVs and 7-GVs. D95 of the PTV decreased to < 90% of the prescribed dose when the FF plan was
shifted 1.1 cm and 1.3 cm in the inferior direction for 5-GVs and 7-GVs. The absolute measured dose showed a
good correlation with the calculated dose in the gradient junction volume. The average percent difference (±SD) in
all measured points was − 0.7 ± 1.6%, and the average dose variations between depths was − 0.18 ± 1.07%.
Conclusion: VGMT can create a linear dose gradient across the junction area in both TH&TH and TH&TD and can
minimize the dose sensitivity to longitudinal setup errors in tomotherapy-based TBI.
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Background
Total body irradiation (TBI) is a radiotherapy technique
that is frequently used as a conditioning regimen for
allogeneic hematopoietic stem cell transplantation
(HCT). TBI used in conjunction with chemotherapeutic
agents has proven to be useful for eradicating malignant
cells. It is also used for immunosuppression to prevent
rejection of donor hematopoietic cells [1, 2].
Conventional TBI is achieved using a linear accelerator
(LINAC) that uses two-opposed fields (right-left or
anterior-posterior) and an extended source-to-skin dis-
tance (SSD), leading to a time-consuming and labor-
intensive procedure, in addition to acute and late toxicity
because of difficulties to spare organs at risk (OARs) [2–
4]. Tomotherapy-based TBI allows sparing of the OARs
and a homogeneous target dose [3, 5–7]. Due to the lon-
gitudinal table movement limit (135 cm) during treat-
ment, however, two plans created in the head-first
position (HFP) and the feet-first position (FFP) are ne-
cessary to include the entire body length. Setup errors of
a few millimeters in the longitudinal direction at the
junction volume can produce dose heterogeneity.
Dose variations due to setup uncertainty at the junc-
tion can be reduced by the feathering technique in
which the longitudinal location of the junction is varied
across treatment fractions [8]. However, this technique
is effort intensive in terms of treatment planning and pa-
tient setup for multiple junctions. Recently, to overcome
the disadvantages of the traditional feathering technique,
gradient dose optimization (GDO) techniques, in which
two overlapping fields, gradually decreasing (or increas-
ing) in junction volume, have been introduced in TBI
planning using tomotherapy [9–12]. However, no studies
have validated the robustness of the GDO-based TBI
plans in the presence of setup errors and the relationship
between dose deviations for different gradient lengths
along the filed overlapping volume.
Tomotherapy-based TBI as intensity-modulated radi-
ation therapy (IMRT) can be delivered via two different
modes: TomoHelical (TH) or TomoDirect (TD). The
most appropriate delivery mode for tomotherapy-based
TBI is yet to be determined. The TH mode is a rota-
tional IMRT and provides a 360-degree beam delivery
that may result in optimal dose conformity [13–15]. The
TD mode uses a fixed gantry angle that includes two
gantry angles instead of rotational beam delivery, which
shortens treatment time and reduces the low dose
spread of radiation in organs at risk [15, 16]. Some
groups have reported the roles and feasibility of TBI
using the tomotherapy; these studies used the same de-
livery mode in HFP and FFP [9, 11, 17, 18]. However,
combining two different delivery modes, each of which
has their own advantages, may lead to more efficient
beam delivery, while reasonably maintaining dosimetric
quality. Therefore, we verified whether GDO can create
a linear dose-gradient at the junction volume with the
combination of two different delivery modes, i.e., TH in
HFP and TD in FFP (TH&TD), as well as with the same
delivery mode (TH&TH).
We describe a GDO technique for TBI using
tomotherapy called, “volumetric gradient matching tech-
nique (VGMT),” to minimize the dose deviation at the
junction volume due to patient setup error. We also re-
port on the robustness of VGMT and the relationships
between gradient lengths and dose variations. The aim
of this work is to verify and propose a VGMT that is
safe and robust to longitudinal setup errors at the junc-
tion area for TBI using tomotherapy. This is the first re-
port to specifically evaluate the feasibility and stability of
the VGMT in TH&TD.
Methods
CT simulation and contouring
Two planning CT image sets (Somatom Sensation Open,
Siemens Healthcare, Erlangen, Germany) were acquired
with HFP and FFP orientations with a 2.5-mm slice
thickness using a solid water phantom of dimensions 15
(width) × 55 (length) × 18 (depth) cm3. For localization
of the matched junction plane, the junction was marked
at mid-phantom using radio-opaque markers. The plan-
ning CT images were imported to RayStation (RaySearch
Laboratories, Stockholm, Sweden) treatment planning
system (TPS) for contouring. For the solid water phan-
tom, planning target volume (PTV) was defined as the
whole phantom. The PTV was then divided into upper
PTV, lower PTV, and gradient volumes (GVs) (Fig. 1a).
The GVs were used to produce a linear dose gradient
across the junction area. To evaluate the impact of the
gradient length, which is the longitudinal length of the
GV, on the robustness of the VGMT-generated TBI plan
at the junction, we tested two different gradient lengths.
The junction comprised 2-cm thick, five- and seven-
gradient volumes (5-GVs and 7-GVs) to create a dose
distribution with a gentle slope: decreasing slope in the
HFP plan and increasing slope in the FFP plan.
Treatment planning for volumetric gradient matching
technique
Treatment planning was performed using the tomother-
apy planning system (TomoTherapy® Inc., Madison, WI,
USA). The center of the entire phantom, the PTV, was
aligned with the gantry isocenter. The prescription dose
was 12 Gy in eight fractions, at two fractions per day.
The plans were optimized such that 95% of the PTV re-
ceived the prescribed dose. Upper and lower PTVs were
covered by prescription dose in the HFP and FFP plans.
TH-IMRT plans were generated on the HFP-CT with
five-GVs (5-GVs) and seven-GVs (7-GVs). TH-IMRT
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and TD-IMRT plans were generated on the FFP-CT
with 5-GVs and 7-GVs. HFP and FFP plans were super-
imposed: TH&TH-5GVs, TH&TH-7GVs, TH&TD-
5GVs, and TH&TD-7GVs. All tomotherapy plans were
computed using the same parameters; field width, pitch,
and modulation factor were 5 cm (for fixed jaw mode),
0.43, and 2.0, respectively. Anterior and posterior beams
were used for TD plans.
A plan with the VGMT was generated using the
gradient volumes by inverse planning. To produce a
linear dose gradient along the superior-inferior direc-
tion at the junction, the dose of each GV was uni-
formly decreased in the HFP and FFP plans using a
pair of maximum dose and minimum dose objective
functions (from 100% of the prescribed dose to 0% of
the prescribed dose). For example, in the plan with 5-
GVs, the last GV was assigned by a maximum value
equal to 20% of the prescription dose and a minimum
value equal to 0% of the prescription dose in the cost
function objective of the TPS. The treatment was de-
livered in two parts with different phantom orienta-
tions: (I) head first from phantom superior end to the
junction plane and (II) after repositioning: Feet first
from inferior end to the junction plane. The phantom
was positioned using the markings on the phantom
surface, and the phantom setup was verified using a
megavoltage-CT (MVCT) scan prior to the HFP and
FFP treatment.
Simulation of setup error
The VGMT should ensure dose homogeneity at the
junction region with the existence of longitudinal setup
errors. To simulate patient setup errors and to evaluate
the robustness of the VGMT, MIM software (version
6.5.6, MIM Software Inc., Cleveland, OH, USA) was
used. Three-dimensional data sets with CTs, structures,
plans, and doses were transferred to the MIM software.
The HFP data sets were fused with the FFP data sets
using the radio-opaque junction markers of the phan-
tom surface. To assess the potential risk associated with
longitudinal setup error, the dose distribution of the
FFP plan was shifted by 5, 10, 15, and 20 mm to the su-
perior (overlap) and inferior (separation) directions
from the matched junction plane. The summed dose
Fig. 1 Volumetric gradient matching technique plan example for TH&TD-5GVs and TH&TD-7GVs. a Definition of upper and lower-PTV in head-first
and feet-first position and gradient volumes (GVs). Dose distribution from each Tomotherapy plan: b TomoHelical IMRT plan in Head-first position,
c TomoDirect IMRT plan in feet-first position, and d sagittal view of summed dose distribution from upper and lower-PTV plans. White dashed
line (along the line A-B) indicates location for drawing the dose profile. The phantom center (PTV center) was aligned to coincide with the gantry
isocenter (point F on (d)). The positions of three dose measurement points are the E, F, and G
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distributions with all simulated setup errors were com-
pared with the original dose distribution (no simulated
setup errors) along the superior-inferior direction in
the matching area. To assess PTV coverage, D95 and
D5 were calculated as indicators of low and high dose
areas, which are particularly relevant for the
separation-simulated plans and for the overlap-
simulated plans, respectively. The calculated D95 and
D5 were compared between the four original plans
(TH&TH-5GVs, TH&TH-7GVs, TH&TD-5GVs, and
TH&TD-7GVs) and the simulated setup error plans.
Treatment plan verification
To evaluate the robustness of the VGMT, the delivered
dose at the junction was verified using ionization cham-
bers (A1SL, Standard Imaging, Middleton, WI, USA)
and compared with the calculated dose of the corre-
sponding shifted plans. During the treatment sessions,
dose measurements were performed with the ionization
chambers positioned on three central points (top, central
and bottom) at the matching area (central transverse
plane): 1 cm below the frontal surface of the phantom,
isocenter, and 1 cm above the bottom surface of the
phantom (Fig. 1d). The delivered dose profiles, especially
in the junction area, were verified using film measure-
ments. Gafchromic film (EBT3, Ashland Inc., Covington,
KY) placed at the central coronal plane as shown in line
A-B on Fig. 1d. Measured profiles were compared to the
profiles from treatment planning calculation. The films
were scanned using a Vidar scanner (Dosimetry Pro Ad-
vantage) and analyzed using RIT software (RIT Inc., Col-
orado Springs. CO) 24 h after irradiation.
Fig. 2 Calculated dose profiles across the junction region for 5-GVs (a) and 7-GVs (b). The dose profiles were obtained along the superior-inferior
axis at the level of the isocenter (direction of the profile as illustrated in Fig. 1d). The blue and green lines are the dose profiles for upper PTV
(head-first position) and lower PTV (feet-first position). The black lines are the sum of the two plans. Solid and dashed lines represent dose profiles
for TH&TH and TH&TD. Both TH&TH and TH&TD plans produced linear dose-gradient profiles at the edges of the individual plans
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Results
Both the TH&TH and TH&TD plans produced linear,
dose-gradient profiles in the junction volume and produced
uniform dose coverage to the PTV using the VGMT (Fig. 2).
Figure 3 illustrate the calculated longitudinal dose profiles
at different depth/lateral positions across the junction area
for TH&TH and TH&TD plans. A constant dose slope in
the junction area was found within acceptable consistency
for five different positions. The dose distributions of the
upper-PTV and lower-PTV using VGMT are reported in
Fig. 1b and c. The final dose distribution showed uniform
coverage of the PTV (Fig. 1d).
Simulation of setup error
Figure 4 shows the dose profiles along the superior-
inferior axis at the level of the isocenter across the junc-
tion area for the TH&TH and TH&TD plans with differ-
ent gradient lengths. Comparison of the dose profiles
shows over/under dosage at the junction depending on
the magnitude of the longitudinal setup error applied to
the FFP plan. For the same setup errors, the dose at the
junction varied less with the larger gradient length (7-
GVs) than with the smaller one (5-GVs). As compared
in Fig. 4a and b, the TH&TH and TH&TD plans shows
similar robustness to the simulated setup errors.
Figure 5 illustrates the DVHs of the PTV for the
VGMT-generated TBI plans using 5-GVs and 7-GVs.
The over- and under-doses were observed on the DVHs,
and these dose heterogeneities increased with increasing
longitudinal setup error. In particular, the underdosage
in the PTV was approximately 10% of the prescribed
dose when the FFP plan was shifted by 1.0 cm in the in-
ferior direction for 5-GVs and 7-GVs. Accordingly, the
overdosage in the PTV was approximately 10% of the
prescribed dose when the FFP plan was shifted by 0.5
cm and 1.0 cm in the superior direction for both 5-GVs
and 7-GVs (Fig. 5a and b). Only slight differences were
observed between the DVH curves for the TH&TH and
TH&TD plans. More robust plans were created using
the longer gradient matching volume than using the
shorter one as compared in Fig. 5a and b.
The D5 of the PTV is expected to be 110% as the
FFP plan is shifted by 0.7 cm and 1.2 cm in the super-
ior direction for 5-GVs and 7-GVs as illustrated in
the fitted graphs in Fig. 6. Similarly, the estimated
shifts in the inferior direction that result in 10% re-
duced PTV D95 were 1.1 cm for 5-GVs and 1.3 cm
for 7-GVs (Fig. 6). In the gradient junction volume,
dose heterogeneity (over/under doses) increased
linearly with the simulated setup error.
Treatment planning verification
The absolute dose measurements showed a good correl-
ation with the calculated doses in the gradient junction
volume (Fig. 7). The total number of measured point
doses was 108. The passing criterion for any point was
Fig. 3 Calculated dose profiles at different positions across the junction region for TH&TH-5GVs (d), TH&TH-7GVs (e), TH&TD-5GVs (f), and
TH&TD-7GVs (g). The dose profiles were obtained along the superior-inferior axis at the level of the five positions (red, blue, green, pink,
and brown circles/dashed arrows on (a, b, and c)). The red, blue, green, pink, and brown lines are the individual and sum dose profiles
at the five different positions (d-g)
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that it should measure within ±5% of the TPS-calculated
dose. The average percent difference (±SD) in all mea-
sured points was − 0.7% (±1.6%), and all point dose differ-
ences were within ±3.5%. The average percent differences
(±SD) were 0.1% (±1.9%), − 0.5% (±1.7%), − 0.5% (±1.7%),
− 0.3% (±1.9%), − 1.2% (±1.6%), − 0.8% (±1.6%), − 0.9% (±
1.5%), − 1.1% (±1.4%), and − 1.1% (±1.5%), respectively, for
the 2.0-, 1.5-, 1.0-, 0.5-, 0-, − 0.5-, − 1.0-, − 1.5-, and − 2.0-
cm simulated setup error (positive value: superior shift,
negative value: inferior shift) (Fig. 7a). The average percent
differences (±SD) were − 2.1% (±1.3%), − 2.0% (±0.8%),
0.3% (±1.0%), and 0.9% (±0.5%) for the TH&TH-5GVs,
TH&TH-7GVs, TH&TD-5GVs, and TH&TD-7GVs,
respectively (Fig. 6b). The average dose variations between
depths were − 0.18% ± 1.07%. Figure 8 shows the results of
treatment plan verification using film dosimetry for the
TH&TH and TH&TD plans. The measured dose profiles
with longitudinal setup errors showed a similar robustness
with the calculated dose profiles in the gradient junction
volume.
Discussion
This study presents a more robust method called the
VGMT to minimize the risk of dose heterogeneity due
to mismatch of abutting plans in TBI using tomother-
apy. VGMT-based TH&TD plan produced a linear
Fig. 4 Comparison of sum dose profiles through a matching area for TH&TH (a) and TH&TD (b). The sum dose profiles were obtained along the
superior-inferior axis at the level of the isocenter (Line A-B in Fig. 1d). To assess the effect of longitudinal setup errors, the FFP plans (lower PTV
plans) were shifted superiorly (positive: overlapped) and inferiorly (negative: separated); no positional shift (black), + 0.5 cm (pink), + 1.0 cm
(orange), + 1.5 cm (green), + 2.0 cm (red), − 0.5 cm (blue), − 1.0 cm (brown), − 1.5 cm (sky blue), and − 2.0 cm (purple). Solid and dashed lines are
the sum dose profile for VGMT using 5-GVs and 7-GVs
Hong et al. Radiation Oncology          (2019) 14:233 Page 6 of 11
gradient dose profile in the junction volume, which was
comparable to that produced by the TH&TH plan.
These low gradient dose junctions help to decrease the
risk of dose uncertainty owing to patient setup error.
Moreover, given the same setup errors, a larger gradient
length decreased the associated dose variation. In this
work, we verified several prerequisites for the implemen-
tation of the VGMT for the TBI using tomotherapy: (a)
the ability of the VGMT to create a linear gradient dose
profile at the junction in TH&TD as well as TH&TH,
(b) to maintain a homogeneous dose at different depths
along the anterior-posterior direction of the phantom
due to the change in beam divergence, and (c) the
relationship between the gradient length and dose varia-
tions associated with setup errors.
Combining the two different delivery modes, i.e.,
TH for the upper body and TD for the lower body,
can be a viable option for tomotherapy-based TBI be-
cause this combination makes the most of each tech-
nique’s advantages. First, TH is more appropriate for
treating the upper body (from vertex to mid-thighs),
where many critical organs are located, because dose
conformity provided by TH is higher than that by TD
due to the 360° beam application while minimizing
radiation dose to OAR [3, 5, 9, 10]. In contrast, using
TD to treat the lower body (from the feet to the
mid-thighs), where there exists no critical organ and
a relatively large setup error is expected, may lead to
reduced treatment time while maintaining treatment
quality. Another advantage of TD, besides simple and
efficient delivery using parallel opposed fields, is that
TD allows beam expansion on both the lateral edges
by a maximum of 5 leaves each. This ensures suffi-
cient dose distribution even in case of dislocation up
to 2 cm from the surface [18]. In order to use the
TH&TD combination for the VGMT, it was necessary
to verify whether the VGMT with the TH&TD deliv-
ery mode could create a dose gradient at the junction
volume. Consequently, the TH&TD VGMT produced
a linear dose-gradient and reduced dose variations
due to setup errors at the matched junction [8, 12,
19], similar to that by the TH&TH VGMT.
Image-guided radiation therapy (IGRT) [20, 21]
using MVCT images is performed before each treat-
ment fraction for online setup correction. Patient po-
sitioning is verified using two MVCT images for the
upper body on the craniocervical and the pelvic areas,
and one MVCT image for the lower body on the
knee area in the TBI using Tomotherapy [9]. Thus,
MVCT for the total body requires a much longer
time. In order to save patient time on the treatment
table, MVCT imaging and registration time must be
reduced. A limited MVCT method (MVCT sampling
of head, chest, and pelvis, with a small number of
slices) seems to be an effective and efficient way to
reduce the patient setup verification time for daily
treatment [6]. Patient setup verification time can be
reduced by combining the limited MVCT method and
TD with the parallel opposed AP-PA beams in FFP.
Our strategy for safe treatment was to define field
margins sufficiently large to avoid repositioning with
MVCT. We opted for more field margins using TD
to minimize the risk of missing targets in the lower
body in FFP.
Uniform dose distribution throughout the body dur-
ing TBI is necessary to suppress immunological rejec-
tion in the recipient and to eliminate residual
Fig. 5 Comparison of dose-volume histograms (DVHs) of the PTV for
VGMT using 5-GVs (a) and 7-GVs (b). Solid and dashed lines of PTV
are the TH&TH and TH&TD; no positional shift (black), + 0.5 cm (pink),
+ 1.0 cm (orange), + 1.5 cm (green), + 2.0 cm (red), − 0.5 cm (blue), −
1.0 cm (brown), − 1.5 cm (sky blue), and − 2.0 cm (purple). Two
vertical dotted lines corresponds to a ± 10% of the prescribed dose
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malignant cells [22, 23]. Therefore, dose uniformity
with depths in the dose-gradient matching volume
must be verified, especially for tomotherapy using the
VGMT. To evaluate the robustness of the VGMT at
various depths, the delivered dose in the junction was
verified using an ionization chamber and was com-
pared with the computed dose of corresponding
plans. Consequently, VGMT produced a constant
dose gradient at three different depths, and the abso-
lute dose measurements showed a good correlation
with the calculated dose measurements in dose-
gradient matching volume. Although there were simu-
lated setup errors, the dose variations between depths
were small (− 0.18 ± 1.07%). Divergence with depth
did not significantly affect the creation of the con-
stant dose gradient with depths in the gradient
matching volume.
We evaluated the relationship between gradient
lengths and dose variations associated with setup er-
rors. A larger gradient length, i.e., a lower gradient
slope, proportionally reduced dose variations associ-
ated with simulated setup errors. For 5-GVs (10 cm
gradient length), calculated deviations of 5.3, 10.6,
15.9, and 21.2% were observed for 5, 10, 15, and 20
mm setup errors. For a 7-GVs (14 cm gradient
length), calculated deviations of 4.0, 8.1, 12.1, and
16.1% were observed for 5, 10, 15, and 20 mm setup
errors. The choice of the gradient length depends on
the clinical requirements, setup reproducibility, and
practicality. The field of the upper and lower body
plans are matched at the mid-thigh; therefore, the
length of patient’s thigh should be considered.
TBI using tomotherapy has been previously reported,
and methods to minimize dose uncertainty at the junc-
tion have been described. Gruen et al. suggested that the
PTV ended the 2-cm set back from the actual cut plane
in both the upper and lower body plan ensure a homo-
geneous dose transition between the upper and lower
body plans [5]. Usui et al. indicated that reducing the
target volume at the field boundary surface by 2.5 cm
was found to be the most robust for a 0.5–1.0-cm setup
error in the cranial–caudal directions [19]. Though this
method is convenient to implement, dose variations at
the junction can be large even in small longitudinal
setup errors.
The GDO technique has recently been adapted to
TBI with helical tomotherapy. Sun et al. [9] and Har-
aldsson et al. [11] introduced the TBI procedure
using the GDO with a 10- or 6-cm gradient length.
In the case of shallow dose gradient, with a 6-cm gra-
dient length, they used a surface scanning system to
position parts of the body that were not covered by
the MVCT, and allowed the longitudinal setup error
to be within 5 mm from the junction markers in
order to maintain a homogeneous junction dose. Al-
though previous studies have shown the implementa-
tion of the GDO, they did not evaluate the
robustness of the GDO and the relationship between
gradient lengths and dose variations in the junction
volume. The GDO technique has been widely used in
craniospinal irradiation (CSI) using intensity modu-
lated proton therapy (IMPT). Many researchers have
reported the relationship between gradient lengths
and dose variation associated setup errors for the
Fig. 6 Relationship between DVH parameters (D5 for overlapped and D95 for separated) and gradient lengths for different setup errors. Positive
and negative position errors represent overlapped (shift to superior) and separated (shift to inferior) scenarios, respectively. Two horizontal dotted
lines corresponds to a ± 10% of the prescribed dose
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GDO. For a 5-cm gradient length, 0.5- and 1.0-cm
setup errors resulted in dose deviations of 10 and
20%, respectively [24, 25]. For a 10-cm gradient
length, 0.5- and 1.0-cm setup errors resulted in dose
deviations of 5 and 10%, respectively [26–28]. Our
data were perfectly consistent with these results. For
the 5-GVs and 7-GVs (10-cm and 14-cm gradient
length), 1.0-cm setup errors resulted in a dose devi-
ation of 10.6 and 8.1%, respectively. A larger gradient
length proportionally reduced the dose deviations as-
sociated with the setup errors.
A limitation of this study is that we used a solid
water phantom to evaluate the robustness of the
VGMT. The phantom based approach does not reflect
the patient induced heterogeneity and the shape of
the patient. However, our study focuses on the dose
changes that occur at the junction. Therefore, being
able to measure at various depths at the junction and
using a shape similar to that of a patient’s thigh were
important. In-phantom measurement is the only
method available to assess the accuracy of junction
dose depending on the depth for different setup er-
rors. In this study, the phantom center was aligned to
coincide with the gantry isocenter. The pitch-
dependent longitudinal dose ripple artifacts depend
on the off-axis distance. When performing the TBI
the thighs are located at off-axis, which can be more
sensitive to the thread effect. Chen et al. reported
that optimal pitches shift downward as the off-axis
distances [29]. Therefore, in order to reduce the
thread effect in real cases, it is important to choose
the optimal pitch.
Fig. 7 Percentage dose difference between measured and TPS calculated dose according to simulated setup errors (a) and VGMT plans (b)
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In order to generate the dose gradient along the longi-
tudinal direction in the junction volume, the PTV should
be divided into equally spaced gradient volumes prior to
inverse dose optimization. Although the VGMT is ro-
bust to setup errors, the procedure can be cumbersome
because delineating the gradient volumes (In our study,
five or seven gradient volumes) can be time consuming.
Further work is needed to simplify the planning proced-
ure to reduce the delineation time in VGMT.
Conclusions
We have evaluated and proposed a robust planning tech-
nique for TBI using tomotherapy to minimize the dose
sensitivity of matched two plans to patient setup error.
Our results showed that the VGMT can create a linear
dose gradient across the junction area in both TH&TH
and TH&TD, and can make the treatment more robust to
longitudinal setup errors in tomotherapy-based TBI. For
5-GVs and 7-GVs (10 and 14 cm gradient length), 1.0-cm
longitudinal setup error resulted in dose deviations of 10.6
and 8.1%, respectively. With TH&TD, treatment planning
and delivery could be more efficient in clinical practice.
This study is expected to provide adequate evidence for




Fig. 8 Dose profile results via film dosimetry in the experimental study for TH&TH (a) and TH&TD (b). The measured dose profiles were obtained
along the superior-inferior axis at the level of the isocenter (Line A-B in Fig. 1d). To assess the effect of longitudinal setup errors, the FFP plans
(lower PTV plans) were shifted superiorly (positive: overlapped) and inferiorly (negative: separated); no positional shift (black), + 0.5 cm (pink), + 1.0
cm (orange), + 1.5 cm (green), + 2.0 cm (red), − 0.5 cm (blue), − 1.0 cm (brown), − 1.5 cm (sky blue), and − 2.0 cm (purple). Solid and dashed lines
are the measured sum dose profiles for VGMT using 5-GVs and 7-GVs
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